Electronic Arts, Western Digital And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Yamana And Pan American Shareholders Approve Proposed Transaction Of All Of The Issued And Outstanding Common Shares Of The Company Following The Sale By Yamana Of Its Canadian Assets
Yamana Gold Inc. (TSX:YRI, NYSE:AUY, LSE:AUY)))) ("Yamana" or the "Company") is pleased to announce that at a special meeting of shareholders held earlier today ("the Meeting"), Yamana
South African Gold Mining Stock AngloGold Ashanti Gets Upgraded, Gold Fields Downgraded
The SPDR Gold Trust (NYSE: GLD) is up 15.8% since Oct. 1, and gold prices are approaching $2,000 per ounce for the first time since April 2022.
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today
Yamana Gold (NYSE:AUY) has outperformed the market over the past 5 years by 6.66% on an annualized basis…
Apple, Amazon, Tesla, Yamana Gold, Gaucho Group: Why These 5 Stocks Are Pulling Investor Eyeballs Today
Major Wall Street indices closed over 1% higher on Friday but closed the weak lower. The non-farm payrolls increased by 261,000 in October, the smallest gain since December 2020. However, the unemployment rate rose to 3.7%. All eyes now turn towards the consumer price inflation due later in the new week.
Block, MasTec, Universal Display And Some Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining more than 400 points on Friday. Here are some big stocks recording gains in today’s session.
Earnings Scheduled For October 27, 2022
Companies Reporting Before The Bell
• Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million.
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
Gainers
PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial met its primary endpoint.
